
The RELIGHT study found that adding retlirafusp alfa to chemotherapy extended overall and progression-free survival in previously untreated gastric and GEJ cancers.
Eric Van Cutsem, MD, PhD, discusses the challenges of using chemotherapy to treat patients with gastric cancer.
Eric Van Cutsem, MD, PhD, at University Hospitals Gasthuisberg/Leuven in Leuven, Belgium, discusses the challenges of using chemotherapy to treat patients with gastric cancer.
Clinical Pearls:
over 11 years ago
Expert Investigators Discuss Emerging Therapies for GI Cancersover 11 years ago
Predictors of Toxicity in Colon Cancer Treatment Identifiedover 11 years ago
Many Biliary Tract Cancers Harbor Actionable Mutationsover 11 years ago
Safety of Regorafenib Confirmed in Patients With mCRC and High PFSover 11 years ago
Pembrolizumab in Advanced Gastric Cancer Treatmentover 11 years ago
Onartuzumab for Gastroesophageal Adenocarcinomaover 11 years ago
FOLFOXIRI plus Bevacizumab for Metastatic Colorectal Cancer